Drug Profile

ENTR 601 50

Alternative Names: ENTR-601-50

Latest Information Update: 17 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Entrada Therapeutics
Class Drug conjugates; Oligonucleotides
Mechanism of Action Dystrophin expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Duchenne muscular dystrophy

Most Recent Events

17 Nov 2025 Entrada Therapeutics plans to initiate phase I/II ELEVATE-50-201 trial for Duchenne muscular dystrophy in the United Kingdom (Parenteral)
07 Nov 2025 Entrada Therapeutics filed for regulatory authorization in U.K. to initiate phase I/II ELEVATE-50-201 trial
06 Nov 2025 Entrada Therapeutics plans files an IND application with the European Medicines Agency for Duchenne Muscular Dystrophy in the second half of 2026 (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com